Canopy Growth Bets On Europe As It Relaunches This Legacy Brand in Germany’s $1B Medical Cannabis Market

Jelena MartinovicBy , Featured Writer
Burn After Reading The 30-second intel for operators and investors

Canopy Growth is relaunching its Tweed brand in Germany's medical cannabis market, which the company says neared $1 billion in annual sales in 2025, and adds three MTL Cannabis strains, with up to five more MTL-derived strains due next month.

  • Operators: Germany's medical market is drawing premium flower and physician-focused branding from a major Canadian producer. Operators competing for European supply should expect more premium strains on shelves through 2026.
  • Investors: Canopy ties its path to positive adjusted EBITDA in fiscal 2027 to MTL's cash-generating business. Q3 revenue was flat at CA$74.5 million, with the net loss narrowing 49%. Fourth-quarter results arrive June 15.
  • Do now: Mark June 15 and review Canopy's fiscal 2026 results for signs of European growth and progress toward positive adjusted EBITDA before updating any sector view.
Short on time? You’re done. Want the numbers?Keep reading ↓

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) is relaunching the Tweed brand in Germany’s medical cannabis market.

The Canadian cannabis company also announced the launch of three premium strains from MTL Cannabis Corp., including Pablo’s Revenge, Dante’s Inferno, and Frost’d Flakes. Canopy said more strains are planned to reach shelves in the European country through 2026, with up to five MTL-derived strains expected to be introduced next month.

Canopy acquired MTL Cannabis earlier this year. That deal expanded premium flower supply for Canopy, enhanced operating execution and ability to meet demand in regulated international medical markets such as Europe.

According to a new report from the Global Cannabis Network Collective and Whitney Economics, Europe is a major factor in shaping the next phase of the global cannabis industry, as it holds the position of the world’s second-largest cannabis market by value.

The growth is driven by medical cannabis programs that amplify, as well as telemedicine adoption, international trade, and stricter EU/UK pharmaceutical manufacturing standards.

Luc Mongeau, CEO of Canopy Growth, recognizes the opportunity.

“We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” Mongeau said in a press release in which the company’s management cited Germany approaching a $1 billion annual medical cannabis market in 2025.

“Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly,” Mongeau continued. “The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care.”

Canopy’s third quarter report of fiscal 2026, which was revealed in February, showed roughly flat year-over-year revenue of CA$74.5 million ($54.3 million), a narrowed net loss year-over-year of 49%, and an adjusted EBITDA loss that narrowed by 17% year-over-year.

Canopy said previously that the integration of a profitable, cash-generating business, such as MTL Cannabis, “supports the Company’s objective of achieving positive adjusted EBITDA during fiscal 2027.”

The company is scheduled to report fourth-quarter and full-year fiscal 2026 results on June 15.

CGC Price Action

Canopy’s shares traded 1.30% lower at $1.52 per share at the time of writing on Friday.

Related coverage

Image
Jelena Martinovic
May 29, 2026
Covers cannabis news, markets and regulation for IgniteIt. Previously wrote about financial markets for Benzinga and Insider Monkey.
Share: